<DOC>
	<DOC>NCT03026166</DOC>
	<brief_summary>The purpose of this multicenter, Phase 1/2, open-label, study is to assess the safety and efficacy of rovalpituzumab tesirine administered in combination with nivolumab or nivolumab and ipilimumab in participants with extensive-stage small cell lung cancer (SCLC).</brief_summary>
	<brief_title>A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>Participants with histologically or cytologically confirmed extensivestage small cell lung cancer (SCLC) with progressive disease after at least one platinumbased chemotherapeutic regimen and with evaluable or measurable disease Eastern Cooperative Oncology Group (ECOG) 01 Adequate hematologic, hepatic, and renal function Has active, known, or suspected autoimmune disease Had prior exposure to an immunooncology or pyrrolobenzodiazepine (PBD)based drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Nivolumab</keyword>
	<keyword>Ipilimumab</keyword>
	<keyword>Rovalpituzumab tesirine</keyword>
	<keyword>Cancer</keyword>
	<keyword>Extensive-Stage Small Cell Lung Cancer</keyword>
</DOC>